Frontlight ResearchEarly access
CompletedPhase 2
Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE)
Key facts
- Who runs it
- HI-Bio, A Biogen Company
- Where
- Georgia, Germany, Greece, Russia, South Korea, Taiwan, and United Kingdom25 sites in 7 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 24 people enrolled
- Started
- 20 Jan 2021
- Ended
- 14 Dec 2023
- Type of study
- Interventional, 2 groups
- Treatments tested
- MOR202
- Record updated
- 7 February 2025
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Subjects ≥ 18 to ≤ 80 years (at date of signing the informed consent form [ICF])
- Urine protein to creatinine ratio (UPCR) of ≥ 3.0 g/g or proteinuria ≥ 3.5 g/24 h
- Estimated glomerular filtration rate (eGFR) ≥ 50 ml/min/1.73 m² (eGFR >30 and < 50 ml/min/1.73 m² can be included provided an interstitial fibrosis and tubular atrophy (IFTA) score of < 25% in a kidney biopsy)
- Not in spontaneous remission despite proper treatment with angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs) (sufficient dose and treatment duration) as per clinical practice and scientific guidelines. If the subject is intolerant to ACEI and ARBs, the reason must be documented and approval for enrollment be obtained from the Medical Monitor
- Systolic blood pressure (BP) ≤150 mmHg and diastolic BP ≤100 mmHg after 5 minutes of rest
- Serum anti-PLA2R antibodies ≥ 50.0 RU/mL determined by Euroimmun ELISA
- Female subjects: A female is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:; Not a female of childbearing potential (FCBP); A FCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 3 months after the last dose of MOR202
Who cannot take part
- Hemoglobin < 80 g/L
- Thrombocytopenia: Platelets < 100.0 x 10\^9/L
- Neutropenia: Neutrophils < 1.5 x 10\^9/L
- Leukopenia: Leukocytes < 3.0 x 10\^9/L
- Hypogammaglobulinemia: Serum immunoglobulins ≤ 4.0 g/L; Subjects may receive supportive therapies to meet the above criteria
- Diabetes mellitus type 2: Subjects with type 2 diabetes mellitus may only enter the clinical trial if a kidney biopsy performed within 6 months prior to screening shows MN without evidence of diabetic nephropathy and diabetes is controlled, as shown by:; Glycated hemoglobin (HbA1c) <8.0 % or 64 mmol/mol; No diabetic retinopathy known; No peripheral neuropathy known
- Total bilirubin, aspartate aminotransferase or alanine aminotransferase >1.5 x ULN, alkaline phosphatase >3.0 x ULN
- B-cells < 5 x 10\^6/L
This trial has no sites in United States.
It has sites in 7 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This 2-arm, multi-center, open-label, parallel-group phase II trial will assess the efficacy, safety and pharmacokinetics/pharmacodynamics of the human antibody MOR202 in subjects with anti-PLA2R antibody-positive membranous nephropathy indicated for immunosuppressive therapy
The 2 groups in the trial
- MOR202 5 DosesTreatment being tested
5 doses administered on Day 1, 8, 15, 29, and 57
Treatment: MOR202
- MOR202 2 DosesTreatment being tested
2 doses administered on Day 1 and 15
Treatment: MOR202
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase IIa, Open-Label, 2-Arm Multicenter Clinical Trial to Evaluate the Efficacy, Safety and PK/PD of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (NewPLACE)
- Publications
- Targeting B Cells and Plasma Cells in Glomerular Disease.Journal of the American Society of Nephrology : JASN, 2025
- Record updated
- 7 February 2025